QuantaMatrix
QuantaMatrix Inc. is a Korean in-vitro diagnostics company founded in 2010 as a spin-off from the Biophotonics and Nano Engineering Lab at Seoul National University, listed on KOSDAQ and operating a European subsidiary. Its flagship product, dRAST™ (direct and Rapid Antimicrobial Susceptibility Test), uses microfluidic agarose channels and time-lapse microscopic imaging to report MIC-based phenotypic susceptibility results directly from positive blood cultures in as low as 4 hours, up to 2 days faster than conventional AST, with Gram-negative and Gram-positive QMAC-dRAST panel kits on CLSI or EUCAST breakpoints. The system and kits are CE-IVD and MFDS (Korea) approved. Danyel Biotech supplies QuantaMatrix's rapid AST solution to clinical microbiology laboratories in Israel.
Danyel Biotech supplies the QuantaMatrix dRAST system and QMAC-dRAST panel kits in Israel, providing local sales and support.
- Rapid antimicrobial susceptibility testing
- Sepsis and bloodstream infection diagnostics
- Antimicrobial stewardship
CE-IVD; MFDS Korea; Korean New Excellent Technology (NET) certification; dRAST solution CE marked under IVDR
Frequently Asked Questions
Who supplies QuantaMatrix dRAST in Israel?
Danyel Biotech supplies the dRAST rapid AST system and the QMAC-dRAST Gram-negative and Gram-positive panel kits in Israel, providing sales and local support.
How fast is dRAST?
dRAST reports MIC-based susceptibility results directly from a positive blood culture in as low as 4 hours, up to 2 days faster than conventional AST, with no pure isolate and no McFarland preparation. Prices are quoted on request.